Atacicept PDUFA Date (Vera Therapeutics)
FDA PDUFA decision date for Atacicept is July 7, 2026. Developed by Vera Therapeutics. Indication: IgA nephropathy (IgAN). Current status: Approved.
Indication
IgA nephropathy (IgAN)
Notes
Breakthrough therapy designation. Strong Phase 3 data in IgAN.
Regulatory details
- Company: Vera Therapeutics
- Therapeutic area: Rare Disease / Nephrology
- Application type: BLA
- Review type: Priority
- PDUFA date: 2026-07-07
- Outcome: Approved